LIGELIZUMAB REDUCES RESCUE MEDICATION USE IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY RESULTS

被引：3
|
作者：
Sitz, K.
Soong, W.
Lanier, B.
Kobayashi, K.
Barve, A.
Hua, E.
Janocha, R.
Severin, T.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2019年 / 123卷 / 05期
关键词：
D O I：
10.1016/j.anai.2019.08.257
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P153
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Rilzabrutinib in Patients With Chronic Spontaneous Urticaria: 12-Week Results From the RILECSU Phase 2 DoseRanging Study
    Maurer, Marcus
    Gimenez-Arnau, Ana
    Ferrucci, Silvia
    Mikol, Vincent
    Sun, Iris
    Mannent, Leda
    Gereige, Jessica
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB373 - AB373
  • [32] Omalizumab retreatment of patients with chronic idiopathic urticaria / chronic spontaneous urticaria following return of symptoms: primary results of the optima study
    Sussman, G.
    Hebert, J.
    Gulliver, W.
    Lynde, C. W.
    Yang, W.
    Chambenoit, O.
    Vieria, A.
    Detakacsy, F.
    Rihakova, L.
    ALLERGY, 2017, 72 : 327 - 327
  • [33] Accompanying conditions in patients with chronic spontaneous urticaria and urticarial vasculitis: Results of a retrospective study
    Akarsu, Sevgi
    Ilknur, Turna
    Ozbagcivan, Ozlem
    Fetil, Emel
    TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, 2015, 49 (01): : 18 - 24
  • [34] Time to Relapse During Treatment-Free FollowUp Without Remibrutinib in Patients With Chronic Spontaneous Urticaria: Subgroup Analysis By Baseline Immunoglobulin-E Levels and Chronic Urticaria Index Status From a Phase 2b Extension Study
    Greiner, Alexander
    Jain, Vipul
    Gimenez-Arnau, Ana
    Tillinghast, Jeffrey
    Lheritier, Karine
    Haemmerle, Sibylle
    Walsh, Pauline
    Nikolaev, Ivan
    Snyder, Robert
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB266 - AB266
  • [35] Time to Onset of Linaclotide Effect On the Bowel Habits in Patients with Chronic Constipation: Results from a Phase 2B Study
    Johnston, Jeffrey M.
    Lavins, Bernard J.
    MacDougall, James E.
    Lembo, Anthony J.
    Schneier, Harvey
    Shiff, Steven J.
    Kurtz, Caroline B.
    Currie, Mark G.
    GASTROENTEROLOGY, 2009, 136 (05) : A537 - A537
  • [36] Omalizumab phase III trials: medication history and baseline characteristics of patients with refractory chronic idiopathic/spontaneous urticaria
    Rosen, K.
    Bradley, M. S.
    Ashby, M.
    H-J, Hsieh
    Georgiou, P.
    Casale, T.
    Maurer, M.
    ALLERGY, 2014, 69 : 444 - 445
  • [37] Safety and tolerability of omalizumab in patients with chronic idiopathic/spontaneous urticaria: Results from the OPTIMA study
    Sussman, Gordon
    Hebert, Jacques
    Gooderham, Melinda
    Gulliver, Wayne
    Lynde, Charles W.
    Papp, Kim A.
    Yang, William H.
    de Takacsy, Frederica
    Chambenoit, Olivier
    Rihakova, Lenka
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB250 - AB250
  • [38] Effect of Linaclotide On Quality of Life in Adults with Chronic Constipation: Results from a Phase 2B Study
    Lavins, Bernard J.
    Johnston, Jeffrey M.
    MacDougall, James E.
    Lembo, Anthony J.
    Schneier, Harvey
    Shiff, Steven J.
    Carson, Robyn T.
    Kurtz, Caroline B.
    Currie, Mark G.
    GASTROENTEROLOGY, 2009, 136 (05) : A71 - A71
  • [39] Metoclopramide Nasal Spray Reduces Symptoms of Gastroparesis in Women, but not Men, With Diabetes: Results of a Phase 2B Randomized Study
    Parkman, Henry P.
    Carlson, Marilyn R.
    Gonyer, Dave
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (07) : 1256 - +
  • [40] Omalizumab Therapy Response with gradual Dose Increase in Patients with chronic spontaneous Urticaria: Results of the OPTIMA Study
    Gulliver, Wayne
    Sussman, Gordon
    Hebert, Jaques
    Lynde, Charles
    Papp, Kim Alexander
    Yang, William H.
    Chambenoit, Olivier
    Vieira, Antonio
    deTakacsy, Frederica
    Rihakova, Lenka
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 11 - 11
12345